Sensitization to myelin basic protein in attacks of multiple sclerosis. A preliminary report

Area of Science:

• Neuroimmunology
• Autoimmunity
• Clinical Immunology

Background:

• Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system.
• Previous attempts to detect antibodies to encephalitogenic basic protein (BP) in MS patients have yielded limited success.
• Encephalitogenic basic protein is a key component of myelin and a potential target in autoimmune neurological disorders.

Purpose of the Study:

• To investigate the presence of antibodies to encephalitogenic basic protein in multiple sclerosis (MS) patients using a novel double immunodiffusion technique.
• To determine if the antibody levels correlate with disease activity (acute exacerbation vs. convalescence).
• To explore the presence of this antibody in other neurological conditions.

Main Methods:

• A sensitive double immunodiffusion assay was employed.
• The assay was used to screen 67 serum samples from patients with multiple sclerosis.
• Serum samples from patients with myasthenia gravis and other neurological diseases were also analyzed for comparison.

Main Results:

• Antibodies to encephalitogenic basic protein were detected in a portion of the multiple sclerosis (MS) sera.
• The antibody was more frequently observed during the convalescent phase of MS than during acute exacerbations.
• Antibodies were also identified in sera from patients with myasthenia gravis and, less frequently, in other neurological diseases.

Conclusions:

• The developed double immunodiffusion method is capable of detecting antibodies to encephalitogenic basic protein in multiple sclerosis (MS) patients.
• The presence of these antibodies may be associated with the recovery phase of MS.
• The findings suggest a potential role for encephalitogenic basic protein autoimmunity in MS and other neurological disorders.